Built for the gap between imaging and dosing.
Targeted radionuclide therapy works best when the dose is tailored to the individual patient. YSOTOPE exists to make that computationally feasible for every nuclear medicine centre, not just specialist dosimetry labs.
Every patient in targeted radionuclide therapy deserves a dose calculated for them, not borrowed from a population average.
The clinical case for personalised dosimetry in theranostics is not new. The pharmacokinetic models, the dosimetric methods, and the published evidence for individual variation have existed for decades. What was missing was the engineering layer that makes routine personalised dosing computationally tractable for departments without a dedicated physics team.
That is what YSOTOPE builds. Not a research tool for specialist centres, but a clinical decision-support layer that slots into the workflow of any oncology department with an active theranostics programme. The science is ours. The integration is designed so that it disappears into the process.
Patient-first dosimetry
The default in our model is always the patient's own pharmacokinetics. Population averages are the fallback, not the starting point.
Transparent modelling
Clinicians can inspect the PK fit, the uncertainty bounds, and the dose kernel assumptions behind every report. No black box.
Built for real workflows
A tool that requires a dedicated physics team to operate is not a solution for most centres. YSOTOPE is designed to fit the session schedule, not to add to it.
Nuclear medicine, machine learning, and clinical physics.
YSOTOPE was founded by clinicians who encountered the gap between imaging data and dosing decisions first-hand, then built the engineering team to close it.
Marina Sole
CEO & Co-founderBackground in clinical translation, AI medical systems, and oncology commercialisation. Marina's experience sits at the intersection of how radiopharmaceutical therapy is planned in practice and the engineering gap that prevents personalised dosimetry from reaching routine departments. She founded YSOTOPE in 2024 to address that gap at the infrastructure level.
Andrei Vascu
CTO & Co-FounderBackground in medical image analysis, computational imaging, and dose-optimisation algorithm design. Andrei's work concentrates on the systems that bridge quantitative molecular imaging data and clinical PK model fitting, including the DICOM ingestion and organ segmentation layers that underpin YSOTOPE's dosimetry pipeline.
Fatima Okonkwo
Chief Medical OfficerMedical physicist and nuclear medicine specialist with a focus on precision oncology protocols and patient dosimetry research. Fatima leads the clinical validation programme at YSOTOPE, overseeing absorbed dose estimation methodology, organ-at-risk dosimetry protocols, and the translation of PK model outputs into actionable clinical dose recommendations.
Based in Barcelona's life sciences district.
YSOTOPE operates from Barcelona's Diagonal corridor, within walking distance of two university hospital nuclear medicine units. The proximity to active theranostics clinical programmes is intentional: rapid-cycle feedback between the clinical and engineering teams is a structural feature of how we develop.
We are incorporated as a Spanish limited company (Sociedad Limitada) and operate under EU data-protection and medical device regulatory frameworks. Our pilot partner hospitals are located in Spain, Germany, and the Netherlands.
Clinicians, physicists, and engineers who care about dosimetry.
We are actively building our clinical partner network and our core team. If you run a nuclear medicine department with an active theranostics programme, or you are a medical physicist or ML engineer with interest in radiopharmaceutical dosimetry, we want to hear from you.